- Home
- / Anpac Bio-Medical Science
Anpac Bio-Medical Science
Stock Price
$3.8
2023-07-21
Market Capitalization
$27 M
2023-07-21
Revenue
¥12 M
FY, 2022
Anpac Bio-Medical Science Summary
Company Summary
- Overview
- Anpac Bio is a biotechnology company focusing on early cancer screening and detection. It markets and sells a multi-cancer screening and detection test that uses its cancer differentiation analysis, or CDA, technology and its proprietary cancer-detection device.
- Type
- Public
- Status
- Active
- HQ
- Shanghai, CN | view all locations
- Website
- http://www.anpacbio.com
- Cybersecurity rating
- Sectors
Table of Contents
Key People
Herbert Yu, Co-founder/Chief Medical Officer
Weidong Dai, China General Manager
Rain Zhang, Chief Financial Officer
Operating MetricsView all
Commercial CDA-Based Tests Sold
41.5K
43.1%
Q3, 2019
CDA-Based Tests for Research Purposes Completed
4.9K
30.5%
Q3, 2019
Blood Samples in Test Database
140K
Q3, 2019
LocationsView all
4 locations detected
Shanghai, Shanghai Shi HQ
China
306, 105 Sinan Rd, Da Pu Qiao, Huangpu Qu
San Jose, CA
United States
2260 Clove Dr #127
Spring House, PA
United States
727 Norristown Rd, Lower Gwynedd Township
Lishui Shi, Zhejiang Sheng
China
Bi Xing Jie, Liandu Qu
Anpac Bio-Medical Science Financials
Summary Financials
- Revenue (H1, 2023)
- ¥4.9M
- Gross profit (H1, 2023)
- ¥897.0K
- Net income (H1, 2023)
- (¥43.5M)
- Cash (H1, 2023)
- ¥495.0K
- EBIT (H1, 2023)
- (¥43.2M)
- Enterprise value
- $26.5M